Daniel Skiest to Cyclopropanes
This is a "connection" page, showing publications Daniel Skiest has written about Cyclopropanes.
Connection Strength
0.059
-
Cummins NW, Neuhaus J, Chu H, Neaton J, Wyen C, Rockstroh JK, Skiest DJ, Boyd MA, Khoo S, Rotger M, Telenti A, Weinshilboum R, Badley AD. Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBioMedicine. 2015 Jul; 2(7):706-12.
Score: 0.030
-
Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. AIDS. 2008 Jan 11; 22(2):275-9.
Score: 0.018
-
Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999 Dec 16; 341(25):1865-73.
Score: 0.010